Parabilis Medicines (NASDAQ:PBLS) Downgraded by Wall Street Zen to "Sell"

Parabilis Medicines logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen downgraded Parabilis Medicines from “hold” to “sell.” Despite the downgrade, analysts’ overall rating remains “Moderate Buy,” with a consensus price target of $40.80.
  • PBLS opened at $27.44, below its 50-day moving average of $29.83; its 12-month trading range is $22.66 to $42.49.
  • Parabilis reported quarterly EPS of ($0.36), beating analysts’ estimate of ($0.40), and revenue of $2.11 million. Analysts expect a full-year loss of $2.56 per share on average.
  • MarketBeat previews the top five stocks to own by December 1st.

Parabilis Medicines (NASDAQ:PBLS - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Several other equities research analysts have also recently commented on PBLS. Weiss Ratings raised shares of Parabilis Medicines from a "sell (d)" rating to a "sell (d+)" rating in a research report on Tuesday. Canaccord Genuity Group initiated coverage on Parabilis Medicines in a report on Monday, November 9th. They issued a "buy" rating and a $39.00 price objective for the company. Finally, HC Wainwright assumed coverage on Parabilis Medicines in a research report on Thursday, October 22nd. They issued a "buy" rating and a $40.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $40.80.

Get Our Latest Research Report on PBLS

Parabilis Medicines Stock Performance

NASDAQ PBLS opened at $27.44 on Friday. The firm has a 50 day simple moving average of $29.83. Parabilis Medicines has a 12-month low of $22.66 and a 12-month high of $42.49.

Parabilis Medicines (NASDAQ:PBLS - Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.04. The business had revenue of $2.11 million for the quarter. On average, analysts predict that Parabilis Medicines will post -2.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Parabilis Medicines

Several hedge funds have recently bought and sold shares of the company. RA Capital Management L.P. boosted its stake in shares of Parabilis Medicines by 0.8% during the 3rd quarter. RA Capital Management L.P. now owns 29,177,964 shares of the company's stock worth $942,156,000 after acquiring an additional 244,593 shares during the period. ARCH Venture Management LLC acquired a new position in shares of Parabilis Medicines during the 2nd quarter worth approximately $175,517,789. venBio Partners LLC bought a new stake in Parabilis Medicines in the 2nd quarter valued at $144,149,497. Alphabet Inc. bought a new stake in Parabilis Medicines in the 2nd quarter valued at $134,647,000. Finally, Regeneron Pharmaceuticals Inc. bought a new stake in Parabilis Medicines in the 2nd quarter valued at $114,042,000.

Parabilis Medicines Company Profile

(Get Free Report)

Parabilis Medicines is a clinical-stage biopharmaceutical company developing medicines for diseases driven by proteins that have been difficult to target with conventional drugs. Its research focuses on macrocyclic peptides designed to address challenging protein interactions, including targets relevant to cancer. The company uses its proprietary Helicon platform to design these peptide-based drug candidates. Parabilis is based in Cambridge, Massachusetts, and was formerly known as Peptone. Parabilis was founded by Gregory Verdine, who serves as the company's chief executive officer.

Further Reading

Analyst Recommendations for Parabilis Medicines (NASDAQ:PBLS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Parabilis Medicines Right Now?

Before you consider Parabilis Medicines, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Parabilis Medicines wasn't on the list.

While Parabilis Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines